Wall Street brokerages expect Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to report sales of $77.74 million for the current quarter, Zacks reports. Four analysts have made estimates for Supernus Pharmaceuticals’ earnings, with the highest sales estimate coming in at $80.30 million and the lowest estimate coming in at $72.88 million. Supernus Pharmaceuticals reported sales of $56.81 million in the same quarter last year, which indicates a positive year over year growth rate of 36.8%. The company is scheduled to announce its next earnings results on Friday, January 19th.

According to Zacks, analysts expect that Supernus Pharmaceuticals will report full-year sales of $77.74 million for the current fiscal year, with estimates ranging from $290.99 million to $298.25 million. For the next fiscal year, analysts expect that the company will report sales of $386.07 million per share, with estimates ranging from $371.36 million to $416.37 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The firm had revenue of $75.83 million during the quarter, compared to the consensus estimate of $68.54 million.

Several equities analysts have recently commented on the stock. FBR & Co assumed coverage on shares of Supernus Pharmaceuticals in a report on Thursday. They issued a “buy” rating and a $53.00 price objective on the stock. Jefferies Group LLC reiterated a “buy” rating and set a $51.00 target price on shares of Supernus Pharmaceuticals in a report on Friday, August 4th. Piper Jaffray Companies reiterated a “hold” rating and set a $41.00 target price on shares of Supernus Pharmaceuticals in a report on Tuesday, September 26th. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $49.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, September 27th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $48.38.

Supernus Pharmaceuticals (NASDAQ SUPN) opened at 41.85 on Friday. The company’s 50-day moving average is $42.84 and its 200 day moving average is $39.71. The stock has a market capitalization of $2.12 billion, a price-to-earnings ratio of 21.12 and a beta of 1.30. Supernus Pharmaceuticals has a one year low of $17.25 and a one year high of $50.05.

ILLEGAL ACTIVITY NOTICE: “$77.74 Million in Sales Expected for Supernus Pharmaceuticals, Inc. (SUPN) This Quarter” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/22/77-74-million-in-sales-expected-for-supernus-pharmaceuticals-inc-supn-this-quarter.html.

In other Supernus Pharmaceuticals news, insider Stefan K.F. Schwabe sold 95,000 shares of the stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $46.59, for a total transaction of $4,426,050.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Padmanabh P. Bhatt sold 5,000 shares of the stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $49.86, for a total transaction of $249,300.00. Following the sale, the senior vice president now owns 12,500 shares in the company, valued at $623,250. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 153,709 shares of company stock worth $7,223,108. 6.70% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. Neumeier Poma Investment Counsel LLC raised its holdings in shares of Supernus Pharmaceuticals by 1.6% in the 2nd quarter. Neumeier Poma Investment Counsel LLC now owns 890,740 shares of the specialty pharmaceutical company’s stock valued at $38,391,000 after purchasing an additional 14,430 shares in the last quarter. Sheets Smith Wealth Management acquired a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $378,000. Royce & Associates LP raised its holdings in shares of Supernus Pharmaceuticals by 22.3% in the 2nd quarter. Royce & Associates LP now owns 159,000 shares of the specialty pharmaceutical company’s stock valued at $6,853,000 after purchasing an additional 29,000 shares in the last quarter. Teachers Advisors LLC raised its holdings in shares of Supernus Pharmaceuticals by 6.9% in the 2nd quarter. Teachers Advisors LLC now owns 466,060 shares of the specialty pharmaceutical company’s stock valued at $20,087,000 after purchasing an additional 29,939 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Supernus Pharmaceuticals by 10.7% in the 1st quarter. Bank of America Corp DE now owns 362,952 shares of the specialty pharmaceutical company’s stock valued at $11,361,000 after purchasing an additional 35,069 shares in the last quarter. Institutional investors own 95.36% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.